Repare Therapeutics Inc. (NASDAQ:RPTX) – Research analysts at Piper Sandler boosted their Q2 2022 EPS estimates for Repare Therapeutics in a research report issued on Sunday, October 10th. Piper Sandler analyst J. Catanzaro now expects that the company will earn ($0.62) per share for the quarter, up from their previous estimate of ($0.67). Piper Sandler also issued estimates for Repare Therapeutics’ Q3 2022 earnings at ($0.67) EPS, Q4 2022 earnings at ($0.80) EPS, FY2022 earnings at ($2.74) EPS, FY2023 earnings at ($3.05) EPS, FY2024 earnings at ($3.58) EPS and FY2025 earnings at ($3.37) EPS.
A number of other brokerages also recently issued reports on RPTX. Bloom Burton started coverage on Repare Therapeutics in a research note on Thursday, September 30th. They set a “buy” rating and a $49.00 target price for the company. Morgan Stanley increased their target price on Repare Therapeutics from $45.00 to $47.00 and gave the stock an “overweight” rating in a research note on Monday, August 16th. Zacks Investment Research downgraded Repare Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday. HC Wainwright assumed coverage on Repare Therapeutics in a research note on Monday, September 13th. They set a “buy” rating and a $54.00 target price for the company. Finally, Guggenheim assumed coverage on Repare Therapeutics in a research note on Monday, June 28th. They issued a “buy” rating and a $46.00 price objective for the company. One analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $47.57.
Repare Therapeutics (NASDAQ:RPTX) last posted its quarterly earnings data on Thursday, August 12th. The company reported ($0.71) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by ($0.10). The business had revenue of $0.28 million during the quarter.
In other Repare Therapeutics news, Director Orbimed Advisors Llc sold 7,094 shares of the stock in a transaction on Monday, August 23rd. The stock was sold at an average price of $34.06, for a total transaction of $241,621.64. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director David P. Bonita sold 887 shares of the stock in a transaction on Tuesday, September 7th. The shares were sold at an average price of $33.93, for a total value of $30,095.91. The disclosure for this sale can be found here. Insiders sold a total of 66,416 shares of company stock valued at $2,261,782 over the last ninety days. 33.60% of the stock is currently owned by company insiders.
Hedge funds have recently bought and sold shares of the company. Royal Bank of Canada boosted its holdings in shares of Repare Therapeutics by 86.0% during the first quarter. Royal Bank of Canada now owns 1,356 shares of the company’s stock worth $41,000 after purchasing an additional 627 shares during the last quarter. UBS Group AG boosted its holdings in shares of Repare Therapeutics by 607.0% during the first quarter. UBS Group AG now owns 1,414 shares of the company’s stock worth $43,000 after purchasing an additional 1,214 shares during the last quarter. Cubist Systematic Strategies LLC raised its position in shares of Repare Therapeutics by 36.1% in the 1st quarter. Cubist Systematic Strategies LLC now owns 4,505 shares of the company’s stock worth $138,000 after buying an additional 1,196 shares during the period. ProShare Advisors LLC purchased a new position in shares of Repare Therapeutics in the 2nd quarter worth $207,000. Finally, JS Capital Management LLC purchased a new position in shares of Repare Therapeutics in the 1st quarter worth $230,000. Institutional investors and hedge funds own 71.52% of the company’s stock.
Repare Therapeutics Company Profile
Repare Therapeutics Inc, a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair.
Featured Story: Cost of Goods Sold (COGS)
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.